|
|
On-Demand Webinar: The Emergence of High Throughput Zebrafish Assays
Cambridge Healthtech Associates' complimentary web conference entitled, The Emergence of High Throughput Zebrafish Assays and Their Future Impact on Safety Decision Making, took place on Wednesday, December 10, 2008 at 10:00 AM EDT (16:00 PM GMT).
You can register to listen to the archived version of this complimentary webinar using the form below. As well, you will be given access to the slides and polling results.
This online session featured the following expert panel:
- Ernie Bush, Ph.D., Vice President and Scientific Director, Cambridge Healthtech Associates
- Claudia Harper, DVM, DACLAM, Director, Preclinical, Amgen, Inc
- Carles Callol, Ph. D., Scientific Director, Biobide
Questions addressed by the panel are as follows:
- What are the primary questions you want answered during early development using a toxicity screening assay?How important is HT in your evaluation process of new screens?
- What advantages would you expect from an in vivo toxicity assay that utilizes low amounts of compounds?
- What advantages would you expect from a highly automated system for conducting in vivo toxicity assays?
- Where/in which step would you apply the zebrafish assay with zebrafish in your company’s workflow?
|